Singapore - Eisai and collaboration partner Merck announce that the China National Medical Products Administration has approved LENVIMA (lenvatinib) as monotherapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Over half of the world's HCC patients come from the Greater Chinese Region.

HBV is considered to be a negative predictor of tumor response to existing drug therapies. Since there are many patients suffering from HCC resulting from HBV in the Greater Chinese Region, lenvatinib is expected to be a new treatment option for HCC patients in this area.

LENVIMA is also approved in the U.S., EU and Japan for the indication.